| Autor: |
Førre, Ø., Waalen, K., Rugstad, H., Berg, K., Solbus, D., Kåss, E. |
| Zdroj: |
Springer Seminars in Immunopathology; Jun1988, Vol. 10 Issue 2/3, p263-277, 15p |
| Abstrakt: |
All the studies so far performed indicate that CS treatment in RA is effective. But it is also clear that CS-induced nephrotoxicity is so far the main problem. However, nephrotoxicity can be minimized by lowering the CS dosage and by ensuring that RA patients subjected to CS therapy have a normal kidney function and no history of hypertension. Hypertrichosis due to CS therapy is also a considerable problem, since the majority of patients with autoimmune diseases are women. Malignant lymphomas are a minor problem as so far there have only been two reported cases among 2500 CS-treated patients with autoimmune diseases. We believe that CS alone or in combination with other drugs will find its place in the treatment of RA and other autoimmune diseases in the future. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink